A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis
Objective: The aim of this study is to evaluate, compare and rank the currently available pharmacological cognitive treatments. Background: Treating cognitive impairment in Parkinson’s disease…Keeping patients out of care facilities— clozapine rescues Parkinson’s patients with troublesome psychosis unresponsive to quetiapine and pimavanserin.
Objective: We describe a single-center cohort of Parkinson patients in crisis with troublesome psychosis unresponsive to quetiapine and pimavanserin, who were rescued by treatment with…How does a diagnosis of Dementia with Parkinson’s influence future care provision?
Objective: To describe the trajectory of Parkinson’s after the onset of dementia including setting of care, frailty levels and mortality rate. Background: Cardiff and Vale…Fibrinogen and CFAH: The two putative markers of Parkinson’s disease with cognitive impairment
Objective: To determine the pathogenic potential of fibrinogen and complement factor H (CFAH) in causing Parkinson’s disease (PD) with cognitive impairment (PDCI)-like symptoms using C57BL/6J…Predicting the development of dementia in patients with Parkinson’s disease by comparing neurosteroids in the blood level
Objective: To increase the reliability of the development of dementia in patients with PD by a comparative assessment of clinical scales and neurosteroids Background: Parkinson's…Data-driven identification of distinct fronto-subcortical and cortical-posterior subtypes of cognitive decline in Parkinson’s disease
Objective: To use a novel data-driven approach, Subtype and Stage inference (SuStain)[1], for identifying distinct subtypes of domain-specific cognitive decline in Parkinson’s disease (PD), and…Lewy body disease clinical subgroups present similar disease progression rates
Objective: To characterize LBD clinical subgroups and identify possible differences in disease progression. Background: Patients with Lewy body disease (LBD) present a wide variety of…The East London Parkinson Disease Project – engaging a diverse population in research
Objective: The objective of this study was to engage a diverse group of people with Parkinson disease (PwP) from East London and build a research…Plasma Alzheimer’s disease biomarkers and cognitive progression in Parkinson’s disease
Objective: To evaluate the relationship between plasma Alzheimer's disease biomarkers and cognitive progression in Parkinson's disease Background: Plasma phosphorylated tau (ptau) isoforms have been recently…
- 1
- 2
- 3
- …
- 6
- Next Page »